Nanjing Leads Biolabs Co., Ltd. LBL-034 Hits 21.8-Month mPFS in RRMM

What happened

Nanjing Leads Biolabs reported updated first-in-human data for LBL-034 in RRMM, showing a 21.8-month median PFS at 400–1,200 μg/kg with predominantly low-grade CRS. The cohort had 56 heavily pretreated patients and median follow-up of 17.8 months. FDA ODD and Fast Track were granted earlier, and Phase III preparation is underway.

Confirmed

Global impact / market context

A long 21.8-month median PFS with mostly low-grade CRS, which means cytokine release syndrome, a common immune side effect, may make LBL-034 look competitive versus approved GPRC5D agents. If Phase III confirms this, it could support faster review paths and higher peak sales potential for Leads Biolabs.

Analyst inference

The update is a mid-stage clinical signal for Leads Biolabs' GPRC5D/CD3 TCE, a bispecific antibody that redirects T cells to kill myeloma cells. Advancing to Phase III raises near-term research and development spending, so investors weigh higher costs against the value inflection of pivotal data and a clear recommended Phase III dose.

Analyst inference

What to watch

1. The company has said Phase III preparation is underway, so watch for trial start timing and any stated recommended Phase III dose, which sets the dose used in the pivotal study. Confirmed
2. Watch whether Leads Biolabs reports confirmatory efficacy and safety versus approved GPRC5D benchmarks, since the company's roughly two-times comparison is its own claim, not independent proof. Proposed
3. Track research and development spending tied to Phase III, because rising costs could pressure cash available before pivotal results arrive. Analyst inference

Evidence

• globenewswire.com